|Articles|December 1, 1995

November/December 1995
Volume 1
Issue 3

Proton Pump Inhibitors Versus H2-Receptor Antagonists for the Treatment of Erosive Gastroesophageal Reflux Disease: A Cost-Comparative Study

Author(s)Martin Zagari, MD, Kathleen F. Villa, MS, James W. Freston, MD, PhD

Download PDF: Proton Pump Inhibitors Versus H2-Receptor Antagonists for the Treatment of Erosive Gastroesophageal Reflux Disease: A Cost-Comparative Study

Articles in this issue

over 30 years ago

Article

Life-Effectiveness Analysis: A Technique for Trading Clinical Life-Years for Societal Life-Years

over 30 years ago

Article

Cost-Benefit Analysis of Epilepsy Treatment by the Neurologist

over 30 years ago

Article

Antihypertensive Therapy: Factors Affecting Medication Compliance and Blood Pressure Control

over 30 years ago

Article

Appropriate Use of Abdominal Ultrasonography in Two Hospitals

over 30 years ago

Article

Long-Term Management of Gastroesophageal Reflux Disease

over 30 years ago

Article

Life-Effectiveness Analysis -- More Shadow Than Light?

over 30 years ago

Article

The Role of the AHCPR in Clinical Guidelines Development

over 30 years ago

Article

Modeling Member Satisfaction in the Management of Pediatric Nocturnal Enuresis

over 30 years ago

Article

The Opportunities for Educational Interventions in the Psychosocial and Behavioral Barriers to Asthma Management

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

Proton Pump Inhibitors Versus H2-Receptor Antagonists for the Treatment of Erosive Gastroesophageal Reflux Disease: A Cost-Comparative Study

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes